Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies
出版年份 2011 全文链接
标题
Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies
作者
关键词
-
出版物
BRITISH JOURNAL OF DERMATOLOGY
Volume 164, Issue 4, Pages 862-872
出版商
Wiley
发表日期
2011-02-17
DOI
10.1111/j.1365-2133.2011.10257.x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pathogenic Mechanisms Shared between Psoriasis and Cardiovascular Disease
- (2012) Ramin Ghazizadeh et al. International Journal of Medical Sciences
- Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents
- (2010) Wolfgang Weger BRITISH JOURNAL OF PHARMACOLOGY
- Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions
- (2010) Batya B. Davidovici et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
- (2010) Christopher E.M. Griffiths et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heart Disease and Stroke Statistics—2010 Update
- (2009) et al. CIRCULATION
- Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
- (2009) Eihab A. Alwawi et al. Dermatologic Therapy
- Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database
- (2009) N. N. Mehta et al. EUROPEAN HEART JOURNAL
- Cardiovascular disease and classic cardiovascular risk factors in patients with psoriasis
- (2009) Alexa Boer Kimball et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- The Risk of Stroke in Patients with Psoriasis
- (2009) Joel M. Gelfand et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psoriasis May Not be an Independent Risk Factor for Acute Ischemic Heart Disease Hospitalizations: Results of a Large Population-Based Dutch Cohort
- (2009) Marlies Wakkee et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample
- (2009) J Schmitt et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
- (2009) Alice Gottlieb et al. LANCET
- Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis
- (2008) Alexa B. Kimball ARCHIVES OF DERMATOLOGY
- The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients
- (2008) A.M. Gori et al. ATHEROSCLEROSIS
- Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction
- (2008) L. Tian et al. BIOSTATISTICS
- The psychosocial and occupational impact of chronic skin disease
- (2008) Judith Hong et al. Dermatologic Therapy
- A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
- (2008) William J. Sandborn et al. GASTROENTEROLOGY
- National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening
- (2008) Alexa B. Kimball et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started